Curia | El poder de la información en las manos del paciente

Oncology Drug Approvals in 2022

Cancer research has seen an immense growth and advancement in recent years. There have been a number of breakthroughs throughout 2022, with a significant number of FDA approvals1 for solid tumors as well as hematological indications, which have significant implications for cancer research and treatment.

Find the FDA drug approvals in the table below:

Month Active Pharmaceutical Ingredient Indication Therapy Type
January 2022 Tebentafusp Unresectable or Metastatic Uveal Melanoma Targeted Therapy
February 2022 Ciltacabtagene Autoleucel Relapsed or Refractory Multiple Myeloma CAR T-cell Therapy
March 2022 Lu 177 vipivotide tetraxetan Metastatic castration-resistant Prostate Cancer Radioligand Therapy
Pembrolizumab Advanced Microsatellite instability high (MSI-H) or Mismatch repair deficient (dMMR) Endometrial Cancer Immunotherapy
Nivolumab; Relatlimab Unresectable or Metastatic Melanoma Immunotherapy
Olaparib Aadjuvant treatment of high-risk early Breast Cancer Targeted Therapy
Nivolumab Neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage Non Small Cell Lung Cancer Targeted Therapy
April 2022 Axicabtagene Ciloleucel Second-line treatment of Large B-cell lymphoma CAR T-cell Therapy
May 2022 Tisagenlecleucel Relapsed or Refractory Multiple Myeloma CAR T-cell Therapy
Nivolumab In combination with chemotherapy and Ipilimumab for first-line Esophageal Squamous Cell Carcinoma Immunotherapy
Ivosidenib Newly Diagnosed Acute Myeloid Leukemia Targeted Therapy
June 2022 Dabrafenib Unresectable or metastatic Solid Tumors with BRAF V600E mutation Targeted Therapy
Lisocabtagene maraleucel Second-line treatment of Large B-cell lymphoma CAR T-cell Therapy
August 2022 Trastuzumab deruxtecan HER2-low Breast Cancer Targeted Therapy
Trastuzumab deruxtecan HER2-mutant Non Small Cell Lung Cancer Targeted Therapy
September 2022 Durvalumab Locally advanced or metastatic Biliary Tract Cancer Immunotherapy
Futibatinib FGFR2 gene fusions or other rearrangement positive Intrahepatic Cholangiocarcinoma Targeted Therapy
October 2022 Tremelimumab Tremelimumab in combination with durvalumab for unresectable Hepatocellular Carcinoma Immunotherapy
Teclistamab Relapsed or Refractory Multiple Myeloma Immunotherapy
November 2022 Cemiplimab In combination with platinum-based chemotherapy for Non Small Cell Lung Cancer Immunotherapy
Tremelimumab In combination with Durvalumab and platinum-based chemotherapy for Non Small Cell Lung Cancer Immunotherapy
Mirvetuximab soravtansine FRα positive, platinum-resistant Ovarian Cancer Antibody-Drug Conjugate
December 2022 Olutasidenib Acute Myeloid Leukemia with a susceptible IDH1 mutation Targeted Therapy
Atezolizumab Alveolar soft part sarcoma Immunotherapy
Adagrasib KRAS G12C mutated Non Small Cell Lung Cancer Targeted Therapy
Mosunetuzumab Relapsed or Refractory Follicular lymphoma Immunotherapy